Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Why do so many seniors with memory loss and dementia never get tested?

  • 'Off switch' for pain discovered: Activating the adenosine A3 receptor subtype is key to powerful pain relief

  • Full-day preschool linked with increased school readiness compared with part-day

  • Diagnosing deafness early will help teenagers' reading development

  • Why do people with autism see faces differently?

  • Sportswomen still second best to sportsmen, in the press

  • Inpatient psychotherapy is effective in Germany

  • How various brain areas interact in decisions

  • Pleasure at another's misfortune is evident in children as young as two

  • Isolation of important centres in brain results in age-related memory deficits

  •